Drug Insights

Unleashing the Power of lemborexant: A Comprehensive Review on R&D Breakthroughs

22 September 2023
4 min read

lemborexant's R&D Progress

Lemborexant is a small molecule drug that targets the orexin receptor. It falls under the therapeutic areas of respiratory diseases, nervous system diseases, and other diseases. The drug is indicated for the treatment of sleep initiation and maintenance disorders, Alzheimer's disease, sleep disorders related to circadian rhythm, sleep apnea (obstructive), and chronic obstructive pulmonary disease.

The originator organization of Lemborexant is Eisai Co., Ltd.The highest R&D phase of this drug is approved.

As a small molecule drug targeting the orexin receptor, Lemborexant offers potential benefits in the treatment of various sleep-related disorders and Alzheimer's disease. Sleep initiation and maintenance disorders are characterized by difficulties in falling asleep or staying asleep, and Lemborexant aims to address these issues. Alzheimer's disease, a neurodegenerative disorder, is also listed as an active indication for Lemborexant, suggesting its potential role in managing sleep disturbances commonly associated with this condition.

Furthermore, Lemborexant's therapeutic areas of respiratory diseases and nervous system diseases indicate its potential broader applications beyond sleep-related disorders. It may have implications in the treatment of respiratory conditions such as chronic obstructive pulmonary disease, which often coexist with sleep disorders.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Mechanism of Action for lemborexant: Orexin receptor antagonist

Orexin receptor antagonists are a type of drug that target and block the activity of orexin receptors in the brain. Orexin receptors are proteins found in the central nervous system that play a role in regulating wakefulness and sleep. By blocking these receptors, orexin receptor antagonists can promote sleep and reduce wakefulness.

 

From a biomedical perspective, orexin receptor antagonists are of interest in the field of sleep medicine. They are used to treat sleep disorders such as insomnia, narcolepsy, and shift work sleep disorder. These drugs help regulate sleep-wake cycles by inhibiting the activity of orexin, a neuropeptide that promotes wakefulness.

Orexin receptor antagonists work by binding to the orexin receptors and preventing the binding of orexin. This blocks the signaling pathway that promotes wakefulness, leading to increased sleepiness and improved sleep quality. By targeting specific receptors involved in sleep regulation, these drugs can provide a more targeted and effective treatment for sleep disorders.

It's worth noting that orexin receptor antagonists should be used under the guidance of a healthcare professional, as they may have potential side effects and interactions with other medications.

Drug Target R&D Trends for lemborexant

According to Patsnap Synapse, as of 1 Sep 2023, there are a total of 10 Orexin receptor drugs worldwide, from 15 organizations, covering 17 indications, and conducting 73 clinical trials.

Based on the analysis of the provided data, Eisai Co., Ltd. is the company with the highest number of drugs in various stages of development targeting the Orexin receptor. The indication of Sleep Initiation and Maintenance Disorders has an approved drug, and several other indications are being investigated. Small molecule drugs are the most common type of drugs in development. The United States and Japan are leading in terms of the number of drugs in different stages of development, with China also showing progress in Phase 3. The competitive landscape for drugs targeting the Orexin receptor is diverse, with multiple companies and countries involved in their development. Future development in this area will likely focus on expanding indications and advancing drugs through clinical trials.

👇Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target

Conclusion

Overall, Lemborexant's approval and active indications highlight its potential as a valuable therapeutic option for patients suffering from sleep-related disorders, Alzheimer's disease, and other associated conditions. 

 A Comprehensive Review of Insulin degludec's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Insulin degludec's R&D Innovations and Drug Target Mechanism
22 September 2023
This article summarized the latest R&D progress of Insulin degludec, the Mechanism of Action for Insulin degludec, and the drug target R&D trends for Insulin degludec.
Read →
Pharmaceutical Insights: Inosine's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Inosine's R&D Progress and its Mechanism of Action on Drug Target
22 September 2023
This article summarized the latest R&D progress of Inosine, the Mechanism of Action for Inosine, and the drug target R&D trends for Inosine.
Read →
 Exploring Ibandronate sodium's Revolutionary R&D Successes
Drug Insights
4 min read
Exploring Ibandronate sodium's Revolutionary R&D Successes
21 September 2023
This article summarized the latest R&D progress of Ibandronate sodium, the Mechanism of Action for Ibandronate sodium, and the drug target R&D trends for Ibandronate sodium.
Read →
Decoding Hydroxocobalamin: A Comprehensive Study of its R&D Trends
Drug Insights
4 min read
Decoding Hydroxocobalamin: A Comprehensive Study of its R&D Trends
21 September 2023
This article summarized the latest R&D progress of Hydroxocobalamin, the Mechanism of Action for Hydroxocobalamin, and the drug target R&D trends for Hydroxocobalamin.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.